Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Intestinal Neoplasms

lutetium has been researched along with Intestinal Neoplasms in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's6 (54.55)24.3611
2020's4 (36.36)2.80

Authors

AuthorsStudies
Bagni, O; D'Agostini, A; Filippi, L; Pirisino, R1
Bodeker, KL; Bushnell, DL1
Blachier, M; Leeuwenkamp, O; Ortiz, R; Smith-Palmer, J; Valentine, W; Walter, T; Werner, A1
Leeuwenkamp, OR; Reed, N; Smith-Palmer, J; Virk, J1
Dalmo, J; Forssell-Aronsson, E; Helou, K; Langen, B; Nilsson, O; Parris, TZ; Rudqvist, N; Schüler, E; Spetz, J; Wängberg, B1
Ćwikła, JB; Kolasińska-Ćwikła, A; Maciejkiewicz, KM; Łowczak, A1
Boucher, JE; Sommers, R1
Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ1
Cives, M; Soares, HP; Strosberg, J1
Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Johanson, V; Kölby, L; Nilsson, O; Schmitt, A; Stridsberg, M; Swärd, C1

Reviews

4 review(s) available for lutetium and Intestinal Neoplasms

ArticleYear
Overview and Current Status of Peptide Receptor Radionuclide Therapy.
    Surgical oncology clinics of North America, 2020, Volume: 29, Issue:2

    Topics: Animals; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Stomach Neoplasms

2020
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Nuclear medicine review. Central & Eastern Europe, 2018, Volume: 21, Issue:2

    Topics: Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Receptors, Peptide; Stomach Neoplasms; Yttrium Radioisotopes

2018
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
    The Medical letter on drugs and therapeutics, 2018, Sep-10, Volume: 60, Issue:1555

    Topics: Animals; Clinical Trials as Topic; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides, Cyclic; Protein Binding; Stomach Neoplasms

2018
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Current opinion in oncology, 2016, Volume: 28, Issue:4

    Topics: Clinical Trials, Phase III as Topic; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Somatostatin; Stomach Neoplasms

2016

Other Studies

7 other study(ies) available for lutetium and Intestinal Neoplasms

ArticleYear
Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
    Clinical nuclear medicine, 2022, 11-01, Volume: 47, Issue:11

    Topics: Aged; Female; Humans; Intestinal Neoplasms; Lutetium; Meningeal Neoplasms; Meningioma; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Stomach Neoplasms

2022
Cost-effectiveness of Lutetium [
    Journal of medical economics, 2020, Volume: 23, Issue:12

    Topics: Cost-Benefit Analysis; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide

2020
Lutetium oxodotreotide (
    BMC cancer, 2021, Jan-05, Volume: 21, Issue:1

    Topics: Cost-Benefit Analysis; Disease Progression; Follow-Up Studies; Humans; Intestinal Neoplasms; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Radiopharmaceuticals; Stomach Neoplasms

2021
Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after
    Nuclear medicine and biology, 2018, Volume: 60

    Topics: Animals; Aspartate Aminotransferase, Cytoplasmic; Female; Intestinal Neoplasms; Intestine, Small; Lutetium; Mice; Mice, Nude; Neuroendocrine Tumors; Octreotide; Radioisotopes; Signal Transduction; Time Factors; Transaminases; Transcription, Genetic; Tumor Suppressor Protein p53

2018
Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
    Clinical journal of oncology nursing, 2018, 10-01, Volume: 22, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Female; Humans; Intestinal Neoplasms; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms

2018
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Endocrine-related cancer, 2013, Volume: 20, Issue:6

    Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate

2013
Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
    Cancer biotherapy & radiopharmaceuticals, 2008, Volume: 23, Issue:1

    Topics: Animals; Carcinoid Tumor; Chromogranin A; Humans; Intestinal Neoplasms; Lutetium; Mice; Mice, Nude; Octreotide; Organometallic Compounds; Radiotherapy Dosage; Receptors, Somatostatin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008